KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Equity Average: 2011-2024

Historic Equity Average for Emergent BioSolutions (EBS) over the last 14 years, with Dec 2024 value amounting to $566.0 million.

  • Emergent BioSolutions' Equity Average rose 25.04% to $559.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $559.4 million, marking a year-over-year increase of 25.04%. This contributed to the annual value of $566.0 million for FY2024, which is 44.42% down from last year.
  • According to the latest figures from FY2024, Emergent BioSolutions' Equity Average is $566.0 million, which was down 44.42% from $1.0 billion recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Equity Average registered a high of $1.5 billion during FY2021, and its lowest value of $566.0 million during FY2024.
  • Moreover, its 3-year median value for Equity Average was $1.0 billion (2023), whereas its average is $1.0 billion.
  • In the last 5 years, Emergent BioSolutions' Equity Average rose by 20.96% in 2020 and then crashed by 44.42% in 2024.
  • Emergent BioSolutions' Equity Average (Yearly) stood at $1.3 billion in 2020, then grew by 20.60% to $1.5 billion in 2021, then decreased by 2.06% to $1.5 billion in 2022, then tumbled by 32.08% to $1.0 billion in 2023, then slumped by 44.42% to $566.0 million in 2024.